Complicated Urinary Tract Infection
4
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
PfizerNEW YORK, NY
2 programs1
1
Ceftazidime - AvibactamPhase 31 trial
NXL104/ceftazidimePhase 21 trial
Active Trials
M&
Iterum TherapeuticsDUBLIN 1, Ireland
1 programSulopenem Etzadroxil/ProbenecidN/A1 trial
Active Trials
NCT04682834No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PfizerCeftazidime - Avibactam
Qilu PharmaceuticalMeropenem- FL058
Merck & Co.CXA-101
PfizerNXL104/ceftazidime
Clinical Trials (5)
Total enrollment: 611 patients across 5 trials
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Start: Jan 2013Est. completion: Sep 2014345 patients
Phase 3Completed
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Start: Oct 2021Est. completion: Aug 2022
Phase 2Unknown
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
Start: Jun 2009Est. completion: Mar 2010129 patients
Phase 2Completed
Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
Start: Nov 2008Est. completion: Jul 2010137 patients
Phase 2Completed
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
N/ANo Longer Available
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space